1. Pomerantz LLP is investigating Mereo for potential securities fraud. 2. Mereo's Phase 3 studies for setrusumab failed to meet primary endpoints. 3. Stock price plummeted 87.64% to $0.28 after study results. 4. Secondary endpoints showed improvements in bone mineral density. 5. No change in the safety profile of the treatment was noted.
FAQ
Why Very Bearish?
The substantial 87.64% drop indicates severe loss of investor confidence, similar to past biotech failures.
How important is it?
The investigation and failed studies create significant risks for MREO investors.
Why Short Term?
The immediate fallout from study results and investigation is likely to affect MREO quickly.
Investor Alert: Pomerantz Law Firm Initiates Investigation into Mereo BioPharma Group plc (MREO)
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Pomerantz Law Firm is currently investigating claims on behalf of investors of Mereo BioPharma Group plc (NASDAQ: MREO). The investigation aims to determine whether Mereo and certain executives or directors have engaged in securities fraud or other unlawful business practices. Interested investors are encouraged to contact Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 7980 for more information.
Mereo's Recent Study Results Prompt Investigation
On December 29, 2025, during pre-market hours, Mereo released results from two Phase 3 clinical studies regarding its treatment, setrusumab, which targets conditions affecting bone metabolism. Unfortunately, neither study met the primary endpoints of demonstrating a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates.
- Primary endpoints were not achieved in both studies.
- Secondary endpoints showed significant improvements in bone mineral density against comparators.
- No change in the safety profile of setrusumab was noted.
As a result of this news, MREO's stock price saw a significant decline, dropping by $2.02 per share or 87.64%, closing at $0.28 per share on the same day.
Pomerantz Law Firm: A Leader in Securities Class Actions
Pomerantz LLP has established itself as a premier firm in corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, who is recognized as the dean of the class action bar, the firm has a rich history of advocating for the rights of victims of securities fraud, fiduciary breaches, and corporate misconduct. Over the last 85 years, Pomerantz has successfully secured numerous multimillion-dollar settlements for class members.
For more details about the firm or to learn about joining the class action related to MREO, please visit www.pomlaw.com.
Contact Information
For further inquiries, please contact:
Danielle Peyton
Pomerantz LLP
Email: dpeyton@pomlaw.com
Phone: 646-581-9980 ext. 7980
Attorney advertising. Prior results do not guarantee similar outcomes.